Europe Novel Drug Delivery Systems Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 8.10 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Novel Drug Delivery Systems Market Analysis
European novel drug delivery system market primarily driven by technological advancements promoting the development of NDDS and the rising need for controlled release of drugs.
Nowadays, for the treatment of chronic disorders as well as for controlling the release of active ingredients from drug products, a unique delivery system, the controlled release drug delivery system (CRDDS) of novel drug delivery, is included in the drug delivery technique. Majority of the active pharmaceutical ingredients are distributed in the form of CRDDS. A controlled drug delivery system is, thus, a very reliable, potential form of novel drug delivery technique, in which the drug is subjected to the appropriate pharmaceutical drug dosage form and its release is predetermined, making the release controlled at particular sites of action (cells, tissues, and organs).
Transdermal patches, implants, nasal systems, microcapsules, etc., are some of the common systems that are considered under controlled release systems. The need for controlled release of drugs is propelling the increasing demand for unique and innovative systems for drug delivery, where this novel drug delivery system plays a significant role in the advancement of controlled release of drugs, thereby driving the growth of the market, over the forecast period.
Europe Novel Drug Delivery Systems Market Trends
This section covers the major market trends shaping the Europe Novel Drug Delivery Systems Market according to our research experts:
Targeted Drug Delivery Systems Segment under Mode of NDDS is Expected to hold the Largest Market Share during the Forecast Period
In the targeted drug delivery system, the drug, which is released at the site of action, then gets attached to the diseased tissue. One of the prime benefits of this mode of drug delivery is controlled and protected action, as the slow, prolonged action of the drug on the diseased tissue for an adequate period of treatment time is expected to provide potential benefits. Targeted drug delivery can be used to treat many diseases, such as the cardiovascular diseases and diabetes. However, the most important application of targeted drug delivery is to treat cancerous tumors. Moreover, Cancer Research UK 2018 report suggests that the population suffering from cancer is expected to increase in the future. As per the report, if recent trends in incidence of major cancers and population growth are consistent, it is predicted there will be 27.5 million new cancer cases worldwide each year by 2040, as compared to 17 million in 2018. In European regions like the UK also expect an increase in incident cases of cancer, as per Cancer Research UK's 2019 report.
These benefits of targeted drug delivery, coupled with the increasing need for technological advancements and a rising need for higher efficacy, owing to the increasing burden of chronic diseases, are propelling the growth of the segment.
Europe Novel Drug Delivery Systems Industry Overview
The market comprises major market players who are primarily focused on research and development for the creation of a stable and safe formulation. The market has been experiencing technological developments on a large scale for the past couple of years. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG, and Sanofi SA.
Europe Novel Drug Delivery Systems Market Leaders
-
GlaxoSmithKline PLC
-
Pfizer Inc.
-
Sanofi SA
-
AstraZeneca
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Europe Novel Drug Delivery Systems Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Technological Advancements Promoting the Development of NDDS
- 4.2.2 Rising Need for the Controlled Release of Drugs
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Guidelines
- 4.3.2 Stability Issues
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Route of Administration
- 5.1.1 Oral Drug Delivery Systems
- 5.1.2 Injectable Drug Delivery Systems
- 5.1.3 Pulmonary Drug Delivery Systems
- 5.1.4 Transdermal Drug Delivery Systems
- 5.1.5 Other Routes of Administration
-
5.2 By Mode of NDDS
- 5.2.1 Targeted Drug Delivery Systems
- 5.2.2 Controlled Drug Delivery Systems
- 5.2.3 Modulated Drug Delivery Systems
-
5.3 Geography
- 5.3.1 Europe
- 5.3.1.1 United Kingdom
- 5.3.1.2 Germany
- 5.3.1.3 France
- 5.3.1.4 Italy
- 5.3.1.5 Spain
- 5.3.1.6 Rest of Europe
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 AstraZeneca PLC
- 6.1.3 Bayer AG
- 6.1.4 GlaxoSmithKline PLC
- 6.1.5 Johnson & Johnson
- 6.1.6 Merck & Co. Inc.
- 6.1.7 Novartis AG
- 6.1.8 Pfizer Inc.
- 6.1.9 F. Hoffmann-La Roche AG
- 6.1.10 Sanofi SA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Europe Novel Drug Delivery Systems Industry Segmentation
As per the scope of this report, novel drug delivery system refers to the approaches, technologies, systems, and formulations for transporting a pharmaceutical compound in the body as required to safely achieve its desired therapeutic effects. It is a novel system for the delivery of drugs, different from the conventional drug delivery systems. The market is segmented by route of administration, mode of NDDS, and geography.
| By Route of Administration | Oral Drug Delivery Systems | |
| Injectable Drug Delivery Systems | ||
| Pulmonary Drug Delivery Systems | ||
| Transdermal Drug Delivery Systems | ||
| Other Routes of Administration | ||
| By Mode of NDDS | Targeted Drug Delivery Systems | |
| Controlled Drug Delivery Systems | ||
| Modulated Drug Delivery Systems | ||
| Geography | Europe | United Kingdom |
| Germany | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe |
Europe Novel Drug Delivery Systems Market Research FAQs
What is the current Europe Novel Drug Delivery System (NDDS) Market size?
The Europe Novel Drug Delivery System (NDDS) Market is projected to register a CAGR of 8.10% during the forecast period (2024-2029)
Who are the key players in Europe Novel Drug Delivery System (NDDS) Market?
GlaxoSmithKline PLC, Pfizer Inc., Sanofi SA, AstraZeneca and Novartis AG are the major companies operating in the Europe Novel Drug Delivery System (NDDS) Market.
What years does this Europe Novel Drug Delivery System (NDDS) Market cover?
The report covers the Europe Novel Drug Delivery System (NDDS) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Novel Drug Delivery System (NDDS) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe NDDS Industry Report
Statistics for the 2024 Europe NDDS market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe NDDS analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
